published that TNF-α blockers not only ameliorate the anti-tumor effect of anti-PD-1 and anti-CTLA-4 combination, but at the same time, reduce irAEs in a preclinical mouse model of colon cancer (74). Here, CTLA4 is linked to colonic neoplasm.